Search

A 33-year-old Chinese male with a 28-year history of atopic dermatitis (AD) presented to our clinic for persisted AD lesions with more frequent flares. Nevertheless, the overall treatment result of dupilumab was rather satisfied with significant improvements of patient's AD lesions (Figure 1P-T), pruritus and quality of life during 30-week follow-up (EASI = 1.7, NRS pruritus = 2/10, DLQI = 8). [Extracted from the article]

Recently, multiple clinical trials of novel drugs for chronic pruritus or prurigo are in progress and show good responses, such as nemolizumab, dupilumab, and serlopitant.3,4 Here, we report a case of refractory PN successfully treated with selective Janus Kinase (JAK) inhibitor baricitinib. It has been also confirmed that the disruption of neuronal JAK1 signaling reduces chronic itch, indicating the therapeutic effect of JAK inhibitor in PN patients.7 Successful therapeutic cases of prurigo with JAK inhibitor, such as baricitinib used in a case of prurigo-type AD, and tofacitinib used in chronic pruritus patients and recalcitrant PN, were reported previously.8-10 In summary, we report a case of MTX intolerant non-atopic PN patient who responded well to baricitinib, particularly in the rapid relief of pruritus. Prurigo nodularis (PN) is a chronic inflammatory skin disease characterized by severe itching and nodular lesions with uncertain etiology and pathogenesis.1 Previous studies show that PN is related to vicious cycles of chronic pruritus and repeated scratching, so rapid itch control is the core element of PN treatment.2 However, there are currently no medications approved for PN, which leads to highly variable practices in the prescription of off-label medications, including topical therapy, phototherapy, and systemic therapy (immunosuppressants, gabapentioids, thalidomide, antidepressants, etc.). [Extracted from the article]

Lichen planopilaris (LPP), an uncommon inflammatory scalp disorder resulting in scarring of alopecia on the scalp, was challenging in treatment due to poor responses to available therapies.1 In this letter, we reported a case of LPP improved with oral baricitinib. The histopathology of an alopecia patch at low magnification, Hematoxylin-Eosin stain 10× (B), and at high magnification, Hematoxylin-Eosin stain 40× (C). gl GLO:ETZ/01nov22:dth15882-fig-0002.jpg PHOTO (COLOR): 2 The changes in dermoscopy examination during the treatment of baricitinib: before treatment (A), after treatment with a dosage of 4 mg daily for 3 months (B), and continuous treatment with a dosage of 2 mg daily for 6 months (C). Physical examination showed erythematous alopecia patches on the scalp's parietal areas, with perifollicular erythema and follicular hyperkeratosis at the margins of expanding alopecic patches (Figure 1A). [Extracted from the article]